Table 4

The association between disease-related variables and TPA among patients with PsA and PsC by linear regression analysis

 Unadjusted modelsAge- and sex-adjusted models
β (95% CI)p Valueβ (95% CI)p Value
Duration of PsA*1.1 (0.6 to 1.6)<0.0010.5 (0.01 to 1)0.04
Duration of psoriasis*,0.3 (0.01 to 0.5)0.04−0.07 (−0.3 to 0.1)0.53
NSAID current use0.3 (−0.95 to 1.51)0.650.92 (−0.05 to 1.89)0.06
NSAID ever use0.14 (−1.13 to 1.42)0.820.91 (−0.1 to 1.93)0.08
DMARD current use0.85 (−0.33 to 2.04)0.160.62 (−0.35 to 1.61)0.21
DMARD ever use0.93 (−0.29 to 2.14)0.130.72 (−0.29 to 1.73)0.16
TNFα blockers current use0.47 (−0.71 to 1.65)0.430.36 (−0.57 to 1.3)0.44
TNFα blockers ever use0.84 (−0.33 to 2.02)0.160.87 (−0.06 to 1.8)0.07
Damaged joint count0.03 (−0.01 to 0.08)0.200.01 (−0.03 to 0.06)0.55
PASI† current−0.08 (−0.16 to 0.01)0.08−0.01 (−0.08 to 0.06)0.88
PASI† highest0.05 (0 to 0.1)0.070.05 (0.01 to 0.09)0.02
Swollen joint count0.13 (−0.11 to 0.37)0.31−0.01 (−0.32 to 0.3)0.94
ESR (mm/h)0.07 (0.02 to 0.11)0.0080.06 (0.02 to 0.1)0.005
  • *10 years increase.

  • †Assessed among PsA and PsC patients.

  • DMARD, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsC, cutaneous psoriasis without arthritis; TNF, tumour necrosis factor; TPA, total plaque area.